Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8 (OPD)

12 May 2014 18:06

RNS Number : 9075G
Pfizer Inc
12 May 2014
Β 

FORM 8 (OPD)

Β 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Identity of the party to the offer making the disclosure:

Pfizer Inc. ("Pfizer")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

AstraZeneca PLC

(d) Is the party to the offer making the disclosure the offeror or the offeree?

Offeror

(e) Date position held:

9 May 2014

(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes, Pfizer Inc.

Β 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Β 

Class of relevant security:

Β 

Ordinary Shares

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

(2) Derivatives (other than options):

Nil

Nil

(3) Options and agreements to purchase/sell:

Nil

Nil

Β 

TOTAL:

Nil

Nil

Β 

Β 

(b) Rights to subscribe for new securities

Β 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

N/A

Β 

Β 

(c) Irrevocable commitments and letters of intent

Β 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

Β 

None.

Β 

Β 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure:

Β 

See below

Β 

Β 

3.1 Pfizer Directors

Β 

Name of Director

Number of Ordinary Shares1 held

Percentage of total issued ordinary shares (excluding treasury shares)

Stephen W. Sanger

161

0.00%

Β 

Β 

3.2 Advisers to Pfizer2

Β 

J.P. Morgan (J.P. Morgan Securities plc and J.P. Morgan Trust Company of Delaware)

Β 

Class of relevant security:

Β 

Ordinary Shares

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

73,878

0.01%

Nil

(2) Derivatives (other than options):

Nil

Nil

(3) Options and agreements to purchase/sell:

Nil

Nil

Β 

TOTAL:

73,878

0.01%

Nil

Β 

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Β 

None.

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

Β 

None.

Β 

Β 

(c) Attachments

Β 

Are any Supplemental Forms attached?

Β 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

Β 

Β 

Date of disclosure:

12 May 2014

Contact name:

Chris Dickinson

Geoff Iles

Telephone number:

+44 (0) 207 134 7302

+44 (0) 207 995 1930

Β 

Β 

Β 


1Β Comprises AstraZeneca ordinary shares held by Stephen W. Sanger 's close relatives, whether directly or in trust (to his knowledge after inquiry).

2Β The information in this section was provided to Pfizer by the relevant adviser

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
FEEQKBDKOBKDQPD
Date   Source Headline
7th May 201411:20 amBUSForm 8.3 - Pfizer Inc
7th May 201410:40 amRNSForm 8.5 (EPT/RI) astrazeneca PLC
7th May 201410:38 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
7th May 201410:36 amRNSForm 8.5 (EPT/RI) Pfizer INC
7th May 201410:31 amRNSRule 2.10 Announcement
7th May 201410:30 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
7th May 201410:29 amRNSForm 8.5 (EPT/RI) Pfizer Inc
7th May 20147:00 amRNSBENEFITS OF A COMBINATION WITH ASTRAZENECA
7th May 20147:00 amRNSForm 8.5 (EPT/NON-RI)
6th May 20146:16 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
6th May 20146:08 pmRNSForm 8.5 (EPT/NON-RI)(OPD)
6th May 20145:15 pmRNSForm 8 (DD) - Pfizer Inc.
6th May 20144:46 pmRNSForm 8.3 - Pfizer Inc
6th May 20144:42 pmRNSForm 8.3 - Pfizer Inc
6th May 20144:16 pmRNSForm 8.5 (EPT/RI)replacement - Pfizer Inc
6th May 20144:14 pmRNSForm 8.5 (EPT/RI) Replacement - Pfizer Inc
6th May 20144:11 pmRNSForm 8.5 (EPT/RI)Replacement - Pfizer Inc
6th May 20144:07 pmRNSForm 8.5 (EPT/RI)Replacement - Pfizer Inc
6th May 20144:05 pmRNSForm 8.5 (EPT/RI) Replacement - Pfizer Inc
6th May 20144:04 pmRNSForm 8.5 (EPT/RI)replacement - Pfizer Inc
6th May 20144:02 pmBUSForm 8.3 - PFIZER INC
6th May 20143:56 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:53 pmRNSForm 8.5 (EPT/RI) Replacement - Astrazeneca PLC
6th May 20143:51 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:51 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:49 pmRNSForm 8.5 (EPT/RI) Replacement - Astrazeneca PLC
6th May 20143:46 pmRNSForm 8.5 (EPT/RI)replacement - Astrazeneca PLC
6th May 20143:34 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:23 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:19 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:19 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:18 pmRNSForm 8.3 - astrazeneca plc
6th May 20143:16 pmRNSForm 8.3 - PFIZER INC
6th May 20143:15 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20143:14 pmBUSForm 8.3 - Pfizer Inc.
6th May 20143:00 pmRNSForm 8.3 - Pfizer Inc.
6th May 20142:51 pmRNSForm 8.3 - [PFIZER INC]
6th May 20142:48 pmBUSForm 8.3 - Pfizer Inc
6th May 20142:31 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
6th May 20141:54 pmRNSForm 8.3 - Pfizer Inc
6th May 20141:48 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20141:28 pmRNSForm 8.3 - Pfizer Inc
6th May 20141:25 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20141:20 pmRNSForm 8.3 - [AstraZeneca Plc]
6th May 20141:14 pmBUSForm 8.3 - Pfizer Inc.
6th May 20141:13 pmRNSForm 8.5 (EPT/RI)
6th May 20141:09 pmRNSForm 8.5 (EPT/NON-RI)
6th May 20141:07 pmBUSForm 8.3 - Pfizer Inc.
6th May 20141:06 pmRNSForm 8.5 (EPT/RI)
6th May 201412:35 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.